查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080390

疫苗市場：2026-2032年全球市場預測（按類型、疫苗配方、疾病、疫苗分類、給藥途徑、劑量、年齡層和最終用戶分類）

Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，疫苗市場規模將成長至 1,523.1 億美元，年複合成長率為 7.76%。

主要市場統計數據
基準年 2025 902.1億美元
預計年份：2026年 971.4億美元
預測年份：2032年 1523.1億美元
複合年成長率 (%) 7.76%

疫苗市場執行摘要

世界衛生組織（世衛組織）指出，疫苗仍是最有影響力的醫療技術之一，每年可預防約350萬至500萬人死亡。疫苗領域涵蓋兒童免疫接種、成人加強針、旅行疫苗、孕婦疫苗、感染疾病疫苗以及疫情防範，構成了一個龐大的產業，其發展受到公共採購、私人創新和全球衛生安全需求的限制。

疫苗產業的變革性變化

疫苗產業正從主要專注於兒童和季節性疫苗的商業模式轉向以生命全程免疫為導向的模式。人口老化推動了對流感疫苗、肺炎球菌疫苗、帶狀皰疹疫苗、呼吸道融合細胞病毒疫苗和新冠疫苗的需求成長，同時，孕婦接種疫苗作為一種在孕婦達到直接接種年齡之前保護她們的一種手段，也正獲得政策支持。

人工智慧在疫苗領域的累積影響

人工智慧（AI）正成為疫苗發現、臨床開發、生產和藥物安全監測各階段的實質驅動力。 AI驅動的抗原設計、蛋白質結構建模、抗原決定位預測和免疫反應模擬有助於在進行成本高昂的臨床試驗之前縮小候選疫苗的範圍。在臨床實踐中，分析技術可用於改善實驗室選擇、受試者招募、方案最佳化和即時安全監測。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區憑藉其龐大的人口規模、不斷壯大的中產階級、大規模的出生群體以及中國、印度、日本、韓國和澳洲等國強大的生產基地，在疫苗市場成長中扮演核心角色。該地區還具有感染疾病監測需求高、國家免疫規劃不斷擴展以及公共部門對生物技術能力投入巨大的特徵。北美地區則繼續保持創新和商業化的重要中心地位，這得益於美國完善的生物醫學研究體系、成熟的監管流程、健全的成人免疫基礎設施以及美加兩國協調一致的公共衛生指南。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，由於新生兒數量大規模、學校免疫接種計劃的實施、旅行需求的復甦、登革熱防控工作的加強以及應對疫情準備的提升，疫苗需求正在不斷成長。同時，區域採購方式仍有很大差異，這取決於各國的收入水準、資金籌措結構和醫療衛生系統能力。海灣合作理事會優先推進免疫接種現代化、數位化健康記錄、全生命週期疫苗接種和策略性採購，這為成人疫苗、旅遊疫苗以及公私夥伴關係創造了機會。

主要疫苗市場的關鍵國家洞察

美國以其強大的資本市場、美國國立衛生研究院（NIH）的研究支持、生物醫學高級研究與發展署（BARDA）的疫情應對資金、免疫諮詢委員會（ACIP）的指南以及大規模的公私免疫管道，引領全球疫苗創新。加拿大強調公共採購、國家免疫指南以及各省和地區之間的公平獲取，而墨西哥則將公共部門需求與區域生產能力和跨境疾病監測重點相結合。巴西憑藉其國家免疫規劃、大規模公共部門採購和已建立的公共疫苗生產能力，成為拉丁美洲領先的疫苗中心。

疫苗產業領導者使用的實用建議

產業領導者應優先考慮涵蓋成人呼吸道疫苗、孕婦疫苗、青少年用疫苗、旅客疫苗和特殊疫苗的全生命週期免疫組合，同時保護其核心的兒童疫苗業務基礎。商業計劃必須與衛生經濟模型一致，這些模型需滿足國家免疫技術諮詢小組提出的證據要求，包括真實世界療效數據、安全性監測、避免住院、提高生產力以及降低醫療保健系統成本。

調查方法

本執行摘要是基於對檢驗的公共衛生、監管和行業證據的系統性回顧。主要資訊來源包括世界衛生組織（WHO）、聯合國兒童基金會（UNICEF）、全球疫苗免疫聯盟（Gavi）、美國疾病管制與預防中心（CDC）、歐洲藥品管理局（EMA）、國家免疫規劃、公共採購文件、同儕審查文獻以及公開的政府和機構資訊披露。

結論

疫苗產業正進入一個更複雜但也充滿機會的階段。常規免疫接種的復興、成人疫苗的推廣、mRNA和重組平台帶來的創新、人工智慧驅動的研發以及對衛生安全的投資，正在重塑疫苗的發現、生產、資金籌措、監管和供應方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：疫苗市場：依類型分類

  • 去活化疫苗
  • 減毒活病毒疫苗
  • 傳訊RNA疫苗
  • 次單位疫苗、重組疫苗、多醣體疫苗、結合疫苗
  • 類毒素疫苗
  • 病毒載體疫苗

第8章：疫苗市場：依疫苗成分分類

  • 疫苗單價
  • 多價疫苗

第9章 疫苗市場：依疾病分類

  • 感染疾病疫苗
    • 流感
    • 甲型肝炎和B型肝炎
    • 脊髓灰質炎
    • COVID-19
    • 肺炎鏈球菌和腦膜炎球菌病菌感染
    • 人類乳突病毒（HPV）
    • 輪狀病毒
    • 登革熱
    • 瘧疾
    • 狂犬病
  • 非感染疾病疫苗
    • 癌症疫苗
    • 過敏疫苗
    • 阿茲海默症疫苗

第10章：疫苗市場：依疫苗分類

  • 預防性疫苗
  • 治療性疫苗

第11章：疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內給藥
  • 口服
  • 皮下

第12章：疫苗市場：依劑量分類

  • 多次給藥
  • 單一劑量

第13章：疫苗市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童
    • 嬰兒
    • 嬰兒

第14章：疫苗市場：依最終用戶分類

  • 學術研究機構
  • 醫院和診所
  • 疫苗接種中心

第15章：疫苗市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Pfizer Inc.
  • BioNTech SE
  • Sinovac BIoTech Ltd.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • AstraZeneca PLC
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat BIoTech Ltd.
  • Biological E. Limited
  • Blue Lake BIoTechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market is projected to grow by USD 152.31 billion at a CAGR of 7.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 90.21 billion
Estimated Year [2026] USD 97.14 billion
Forecast Year [2032] USD 152.31 billion
CAGR (%) 7.76%

Vaccines Executive Summary

Vaccines remain one of the highest-impact health technologies, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The vaccines landscape spans pediatric immunization, adult boosters, travel vaccines, maternal vaccination, therapeutic cancer vaccines, and epidemic preparedness, creating a broad industry shaped by public procurement, private innovation, and global health security needs.

Demand is being driven by routine immunization recovery after COVID-19 disruptions, rising use of newer platforms such as mRNA, viral vectors, recombinant proteins, and conjugate technologies, expanded human papillomavirus and pneumococcal programs, and stronger government stockpiling for pandemic and outbreak response. WHO and UNICEF estimates also show persistent access gaps, including 14.5 million zero-dose children in 2023, making coverage recovery and equitable delivery central to long-term vaccine strategy. For industry leaders, success depends on evidence-based portfolio prioritization, resilient supply chains, regulatory agility, and access models that improve immunization coverage while sustaining commercial performance.

Transformative Shifts in the Vaccines Landscape

The vaccine industry is shifting from a primarily pediatric and seasonal business toward a life-course immunization model. Aging populations are increasing demand for influenza, pneumococcal, shingles, respiratory syncytial virus, and COVID-19 vaccines, while maternal immunization is gaining policy support as a way to protect infants before they are eligible for direct vaccination.

Technology is also reshaping competition. mRNA platforms demonstrated global scalability during the COVID-19 response, and developers are now applying nucleic acid, recombinant protein, conjugate, viral-vector, and combination approaches to influenza, RSV, oncology, and emerging infectious disease vaccines. At the same time, governments are emphasizing domestic manufacturing, fill-finish capacity, cold-chain resilience, genomic surveillance, and faster regulatory pathways to reduce dependence on concentrated supply hubs and strengthen epidemic readiness.

Cumulative Impact of Artificial Intelligence on Vaccines

Artificial intelligence is becoming a practical accelerator across vaccine discovery, clinical development, manufacturing, and pharmacovigilance. AI-enabled antigen design, protein structure modeling, epitope prediction, and immune-response simulation can help narrow candidate selection before costly trials. In clinical operations, analytics can improve site selection, participant recruitment, protocol optimization, and real-time safety monitoring.

The cumulative impact is faster cycle times and more targeted investment decisions, but responsible adoption is essential. Vaccine developers must validate AI outputs against laboratory and clinical evidence, protect patient data, reduce model bias, and maintain transparent regulatory documentation. Used well, AI can strengthen pandemic readiness, optimize strain selection, improve demand forecasting, enhance quality control, and improve post-market signal detection without replacing established scientific and regulatory standards.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is central to vaccine growth because of its population scale, expanding middle class, large birth cohorts, and manufacturing depth in China, India, Japan, South Korea, and Australia. The region is also shaped by high infectious-disease surveillance needs, national immunization expansion, and public investment in biotechnology capacity. North America remains a leading innovation and commercialization hub, supported by the U.S. biomedical research ecosystem, advanced regulatory pathways, robust adult immunization infrastructure, and coordinated public-health guidance in the United States and Canada.

Latin America shows rising demand for pediatric, HPV, influenza, dengue, and outbreak-response vaccines, with Brazil and Mexico anchoring public immunization programs and regional manufacturing ambitions. Europe combines mature vaccination programs with strong regulatory oversight through the European Medicines Agency and national technical advisory groups, while also prioritizing adult immunization, pharmacovigilance, antimicrobial-resistance prevention through vaccination, and supply resilience following pandemic-era procurement lessons.

The Middle East is investing in health security, procurement modernization, digital immunization systems, and domestic biologics capacity, particularly across high-income Gulf markets that are expanding preventive care and travel-related vaccination infrastructure. Africa represents both an urgent coverage opportunity and a long-term manufacturing priority, as the African Union and Africa CDC support expanded local vaccine production, stronger cold-chain systems, improved last-mile delivery, and more resilient supply networks to reduce dependence on imported vaccines.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are expanding vaccine demand through sizable birth cohorts, school-based immunization programs, travel recovery, dengue prevention priorities, and stronger pandemic preparedness, while regional procurement approaches still vary widely by country income, financing structures, and health system capacity. The GCC is prioritizing immunization modernization, digital health records, life-course vaccination, and strategic purchasing, creating opportunities for adult vaccines, travel vaccines, and public-private supply partnerships.

The European Union remains influential through centralized regulatory standards, joint procurement experience, pharmacovigilance coordination, and health security planning under regional preparedness frameworks. BRICS economies combine large population needs with growing domestic manufacturing, public-sector procurement, and technology-transfer priorities, making them important for high-volume immunization delivery, localized production, and diversified global vaccine supply.

G7 countries lead in vaccine R&D financing, regulatory science, premium-market adoption, and preparedness funding, especially for adult, maternal, respiratory, and specialty vaccines. NATO members increasingly view vaccine availability as part of biodefense, military readiness, force health protection, and civil resilience, reinforcing the link between immunization, emergency preparedness, and national security.

Key Country Insights Across Major Vaccine Markets

The United States leads global vaccine innovation through deep capital markets, NIH-supported research, BARDA preparedness funding, ACIP guidance, and large commercial and public immunization channels. Canada emphasizes public procurement, national immunization guidance, and equitable access across provinces and territories, while Mexico combines public-sector demand with regional manufacturing potential and cross-border disease surveillance priorities. Brazil is a major Latin American anchor through its National Immunization Program, large public-sector purchasing role, and established public vaccine production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature vaccine markets with strong regulatory systems, adult immunization needs, public purchasing mechanisms, and established pharmacovigilance practices. The United Kingdom has a prominent national immunization advisory structure and clinical research capacity; Germany and France bring advanced biomedical ecosystems and strong public-health infrastructure; Italy and Spain continue to focus on pediatric, elderly, and regional coverage improvements. Russia maintains domestic vaccine capabilities and sovereign supply priorities. China and India are critical to global scale: China has a large domestic immunization base and expanding biotechnology capabilities, while India is one of the world's largest vaccine suppliers by volume and a key source for routine immunization programs in low- and middle-income countries.

Japan, Australia, and South Korea are high-value Asia-Pacific vaccine markets with strong quality standards, aging populations, and active life-science ecosystems. Japan's demographic profile supports demand for adult and elderly immunization, Australia is important for seasonal influenza surveillance and regional public-health preparedness, and South Korea is strengthening its role in advanced biomanufacturing, clinical research, and regional epidemic-response partnerships.

Actionable Recommendations for Vaccine Industry Leaders

Industry leaders should prioritize life-course immunization portfolios, including adult respiratory, maternal, adolescent, travel, and specialty vaccines, while protecting core pediatric franchises. Commercial plans should be aligned with national immunization technical advisory group evidence requirements, real-world effectiveness data, safety monitoring, and health-economic models that demonstrate avoided hospitalizations, productivity gains, and health-system savings.

Operationally, organizations should diversify antigen, adjuvant, vial, stopper, lipid nanoparticle, cold-chain, and fill-finish supply; build regional manufacturing partnerships; and invest in end-to-end supply visibility. Leaders should also embed AI governance, strengthen pharmacovigilance, support vaccine confidence campaigns, improve healthcare-provider education, and design access models for low- and middle-income countries through tiered pricing, pooled procurement, donation mechanisms, and technology transfer where appropriate.

Research Methodology

This executive summary is based on a structured review of verified public-health, regulatory, and industry evidence. Core sources include the World Health Organization, UNICEF, Gavi, the Vaccine Alliance, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization programs, public procurement documents, peer-reviewed literature, and publicly available government and institutional disclosures.

The analysis combines disease-burden trends, immunization coverage data, technology-platform developments, regulatory patterns, procurement dynamics, cold-chain requirements, and regional manufacturing priorities. Findings were synthesized to identify durable strategic themes rather than short-term fluctuations, with emphasis on evidence that is internationally recognized, reproducible, and relevant to vaccine developers, manufacturers, distributors, healthcare providers, policymakers, and investors.

Conclusion

The vaccines sector is entering a more complex but opportunity-rich phase. Routine immunization recovery, adult vaccine expansion, mRNA and recombinant-platform innovation, AI-assisted development, and health-security investment are reshaping how vaccines are discovered, manufactured, financed, regulated, and delivered.

Winning organizations will combine scientific excellence with access discipline. They will need to prove clinical value, scale reliably, navigate regional policy differences, and support public trust. As governments and healthcare systems continue to treat immunization as both preventive care and strategic preparedness, vaccines will remain central to global health outcomes and long-term life-science growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vaccines Market, by Type

  • 7.1. Inactivated Vaccines
  • 7.2. Live-Attenuated Vaccines
  • 7.3. Messenger RNA Vaccines
  • 7.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 7.5. Toxoid Vaccines
  • 7.6. Viral Vector Vaccines

8. Vaccines Market, by Vaccine Combination

  • 8.1. Mono-Valent Vaccines
  • 8.2. Multi-Valent Vaccines

9. Vaccines Market, by Disease Indication

  • 9.1. Infectious Disease Vaccines
    • 9.1.1. Influenza
    • 9.1.2. Hepatitis A & B
    • 9.1.3. Polio
    • 9.1.4. COVID-19
    • 9.1.5. Pneumococcal & Meningococcal Disease
    • 9.1.6. Human Papillomavirus HPV
    • 9.1.7. Rotavirus
    • 9.1.8. Dengue
    • 9.1.9. Malaria
    • 9.1.10. Rabies
  • 9.2. Non-Infectious Disease Vaccines
    • 9.2.1. Cancer Vaccines
    • 9.2.2. Allergy Vaccines
    • 9.2.3. Alzheimer's Vaccines

10. Vaccines Market, by Vaccine Classification

  • 10.1. Preventive Vaccines
  • 10.2. Therapeutic Vaccines

11. Vaccines Market, by Route of Administration

  • 11.1. Intramuscular
  • 11.2. Intranasal
  • 11.3. Oral
  • 11.4. Subcutaneous

12. Vaccines Market, by Dosage

  • 12.1. Multi Dose
  • 12.2. Single Dose

13. Vaccines Market, by Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric
    • 13.3.1. Infants
    • 13.3.2. Toddlers

14. Vaccines Market, by End User

  • 14.1. Academic & Research Institutes
  • 14.2. Hospitals & Clinics
  • 14.3. Vaccination Centers

15. Vaccines Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Vaccines Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Vaccines Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Pfizer Inc.
  • 19.2. BioNTech SE
  • 19.3. Sinovac Biotech Ltd.
  • 19.4. Moderna, Inc.
  • 19.5. Merck & Co., Inc.
  • 19.6. GlaxoSmithKline PLC
  • 19.7. Sanofi S.A.
  • 19.8. Johnson & Johnson Services, Inc.
  • 19.9. AstraZeneca PLC
  • 19.10. Abbott Laboratories
  • 19.11. Astellas Pharma Inc.
  • 19.12. Bavarian Nordic A/S
  • 19.13. Bharat Biotech Ltd.
  • 19.14. Biological E. Limited
  • 19.15. Blue Lake Biotechnology
  • 19.16. Capricor Therapeutics, Inc.
  • 19.17. Chongqing Zhifei Biological Products Co., Ltd.
  • 19.18. CSL Limited
  • 19.19. CureVac N.V.
  • 19.20. Daiichi Sankyo Company, Limited.
  • 19.21. Gennova Biopharmaceuticals Limited
  • 19.22. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 19.23. Incepta Pharmaceuticals Ltd.
  • 19.24. Inovio Pharmaceuticals, Inc.
  • 19.25. Novavax, Inc.
  • 19.26. Serum Institute of India Pvt. Ltd.
  • 19.27. Takeda Pharmaceutical Company Limited
  • 19.28. VBI Vaccines Inc.
  • 19.29. Versatope Therapeutics
  • 19.30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TOXOID VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TOXOID VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEPATITIS A & B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEPATITIS A & B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEPATITIS A & B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DENGUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLERGY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLERGY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLERGY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALZHEIMER'S VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALZHEIMER'S VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALZHEIMER'S VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TODDLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TODDLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TODDLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GCC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GCC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 224. GCC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. G7 VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 260. G7 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 268. NATO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. NATO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 272. NATO VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 356. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 357. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 361. RUSSIA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 368. RUSSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 369. RUSSIA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 370. ITALY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 371. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 372. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 373. ITALY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 374. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 375. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 376. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 377. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 378. ITALY VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 379. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 380. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 381. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 382. SPAIN VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 383. SPAIN VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 384. SPAIN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 385. SPAIN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 386. SPAIN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 387. SPAIN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 388. SPAIN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 389. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 390. SPAIN VACCINES MARKET SIZE, BY DOSAGE, 2018-203